1 Correction to: Drugs 2018; 78(1):65–98 https://doi.org/10.1007/s40265-017-0851-9
Incorrect section headings
Section heading 5.2, which currently reads 5.2 Meropenem–Relebactam
Should read
5.2 Meropenem–Vaborbactam
Section heading 6.2, which currently reads 6.2 Meropenem–Relebactam
Should read
6.2 Meropenem–Vaborbactam
Section heading 7.2, which currently reads 7.2 Meropenem–Relebactam
Should read
7.2 Meropenm–Vaborbactam
Section heading 8.2, which currently reads 8.2 Meropenem–Relebactam
Should read
8.2 Meropenem–Vaborbactam
Section heading 9.2, which currently reads 9.2 Meropenem–Relebactam
Should read
9.2 Meropenem–Vaborbactam
Section heading 9.4, which currently reads 9.4 Meropenem–Relebactam
Should read
9.4 Meropenem–Vaborbactam
Section heading 10.2, which currently reads 10.2 Meropenem–Relebactam
Should read
10.2 Meropenem–Vaborbactam
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhanel, G.G., Lawrence, C.K., Adam, H. et al. Correction to: Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs 78, 787 (2018). https://doi.org/10.1007/s40265-018-0910-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-018-0910-x